H2-Pharma, LLC, a privately held pharmaceutical company, has re-launched Xenical (orlistat) 120 mg capsules via its newly formed branded division. This opportunity arose due to the partnership with Cheplapharm Arzneimittel GmbH, who has recently completed its acquisition of Xenical from F. Hoffman-La Roche/Genentech, and has agreed to give H2-Pharma the exclusive distribution rights to market Xenical in the US.
Xenical, indicated for obesity management, received marketing approval from the US Food and Drug Administration in 1999, and is the only prescription Orlistat product in the US.
H2-Pharma's president, Bryce M. Harvey said, "We are excited to re-launch Xenical as it represents the first branded product that H2-Pharma has brought to the US market. Our brand strategy is to seek out underserved products that have the potential to grow with the right focus and commercialization efforts. Xenical is an established brand that is reflective of the type of branded products we are seeking, and we are eager to maximize its potential."
H2-Pharma LLC is a privately-held pharmaceutical company focused on the sales, marketing and development of brand and generic products.
Cheplapharm is a family owned pharmaceutical company with its headquarters situated in Germany and offering branded products on a global level.